CStone Pharmaceuticals (HKG:2616) enrolled its first patient in its global multicenter phase 1B clinical trial for its CS5001 anti-tumor drug, according to a Thursday filing with the Hong Kong Exchange.
The drug is indicated for anti-tumor activity in both solid tumors and lymphomas, showing "robust" anti-tumor activity in its Phase 1A trials, the filing said.
Shares were down nearly 2% in morning trade Thursday.
Price (HKD): $2.49, Change: $-0.070, Percent Change: -2.73%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。